Fecal transplantation poses dilemma for FDA

  title={Fecal transplantation poses dilemma for FDA},
  author={Mark Ratner},
  journal={Nature Biotechnology},
401 New England Journal of Medicine in January 2013 (NEJM 368, 407–415, 2013). The study was stopped early when C. difficile-associated diarrhea resolved in 13 of the 16 patients in the FMT-treated group, after a single infusion. Two of the three remaining patients were also cured after repeating the procedure. For the FDA, fecal transplant fits the definition of a biological agent and not transplanted tissue. In an April 2013 letter to the American Gastroenterological Association (AGA), it… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 22 times over the past 90 days. VIEW TWEETS